Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 21,489 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Myelofibrosis (MF)
Interventions: Navitoclax, Ruxolitinib, Best Available Therapy (BAT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 41
States / cities: Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more

Conditions: Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma, Lymphoma
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 97
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more

Conditions: Breast Cancer
Interventions: Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more

Conditions: Psychotic Disorders, Psychosis, Psychotic Episode
Interventions: Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Edema
Interventions: Dexamethasone Phosphate Ophthalmic; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: Alzheimer Disease
Interventions: MAR; Drug
Lead sponsor: Noah Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more

Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
Interventions: Decitabine, PDR001, MBG453, Azacitidine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Portland, Oregon • Houston, Texas

Conditions: Respiratory Infection, Elderly
Interventions: Vitamin E; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1997
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C
Interventions: Sofosbuvir/Velpatasvir Treatment for 14 days; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 4 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions: Screening; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide; Combination Product · Procedure · Drug
Lead sponsor: Imvax; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Jacksonville, Florida • Boston, Massachusetts • Detroit, Michigan + 15 more

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 40 Years and older · Male only
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Duarte, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more

Conditions: Obesity, Prediabetic State
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Cancer
Interventions: Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 26 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more

Conditions: Brain and Central Nervous System Tumors
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Pain
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more

Conditions: Atrophy of Edentulous Alveolar Ridge, Partial Edentulism
Interventions: Two implant designs in a Sinus Bone Augmentation Procedure, Two implant designs in a Sinus Floor Elevation Procedure; Device
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 21 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Jaw, Edentulous, Partially
Interventions: Straumann Bone Level Implants, 4.1 mm implant diameter, Straumann Bone Level Implants, 3.3 mm implant diameter; Device
Lead sponsor: Institut Straumann AG; Industry
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
Interventions: AZD0466; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more

Search by objective public record fields.

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Pilot Study of Motivational Interviewing for Loved Ones

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

The Dual Antiplatelet Therapy Study (DAPT Study)

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Vitamin E and Infection in the Elderly

HCV Post-Exposure Prophylaxis for Health Care Workers

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Biomarker for Infection Risk in CLL and MM

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Effect of Melatonin on Cardiometabolic Risk- FULL

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Sinus Floor Elevation

Straumann Roxolid Multi-Center Study

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors